| 000 | 01860 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516120423.0 | ||
| 264 | 0 | _c20130911 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1532-0987 | ||
| 024 | 7 |
_a10.1097/INF.0b013e31827b0d24 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNissen, Michael D | |
| 245 | 0 | 0 |
_aA randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. _h[electronic resource] |
| 260 |
_bThe Pediatric infectious disease journal _cApr 2013 |
||
| 300 |
_a364-71 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntigens, Bacterial _xgenetics |
| 650 | 0 | 4 | _aAustralia |
| 650 | 0 | 4 |
_aBacterial Proteins _xgenetics |
| 650 | 0 | 4 | _aBlood Bactericidal Activity |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMeningococcal Infections _ximmunology |
| 650 | 0 | 4 |
_aMeningococcal Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aNeisseria meningitidis, Serogroup B _xgenetics |
| 650 | 0 | 4 |
_aRecombinant Proteins _xgenetics |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 |
_aVaccines, Synthetic _xadministration & dosage |
| 700 | 1 | _aMarshall, Helen S | |
| 700 | 1 | _aRichmond, Peter C | |
| 700 | 1 | _aJiang, Qin | |
| 700 | 1 | _aHarris, Shannon L | |
| 700 | 1 | _aJones, Thomas R | |
| 700 | 1 | _aJansen, Kathrin U | |
| 700 | 1 | _aPerez, John L | |
| 773 | 0 |
_tThe Pediatric infectious disease journal _gvol. 32 _gno. 4 _gp. 364-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/INF.0b013e31827b0d24 _zAvailable from publisher's website |
| 999 |
_c22228048 _d22228048 |
||